Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.56 |
| ▸ | BACE1 | P56817 | 3/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591657 | 0.91 | SMN1; SMN2 (0.75) | SMN1; SMN2AKR1C3AKR1C2BACE1ALDH1A1 | |
| Acrylic Acid SCHEMBL27869593 | 0.91 | SMN1; SMN2 (0.54) | SMN1; SMN2AKR1C3AKR1C2BACE1HDAC8 | |
| SCHEMBL8202718 | 0.90 | PRKAB2 (0.55) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1LMNA | |
| SCHEMBL8782870 | 0.90 | CYP1A2 (0.57) | SMN1; SMN2AKR1C3AKR1C2BACE1HDAC8 | |
| SCHEMBL22319299 | 0.88 | ALDH1A1 (0.57) | SMN1; SMN2AKR1C3AKR1C2BACE1HDAC8 | |
| SCHEMBL9683222 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2AKR1C3AKR1C2BACE1ALDH1A1 | |
| SCHEMBL9151080 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1CYP1A2 | |
| SCHEMBL8566031 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2AKR1C3AKR1C2ALDH1A1CYP1A2 | |
| SCHEMBL6775841 | 0.87 | KDM4E (0.62) | SMN1; SMN2AKR1C3AKR1C2BACE1HDAC8 | |
| SCHEMBL5342329 | 0.86 | SMN1; SMN2 (0.84) | SMN1; SMN2AKR1C3AKR1C2BACE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118712660-A | High-porosity dry-method diaphragm for lithium ion battery and preparation method thereof | 宁波长阳科技股份有限公司 | 2024-09-27 | — | — | CN | claimed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | claimed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | claimed |
| US-20250302861-A1 | SMALL RNA AND USE THEREOF IN TREATMENT OF HYPERLIPIDEMIA | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2025-10-02 | — | — | US | disclosed |
| CN-118712660-B | High-porosity dry-method diaphragm for lithium ion battery and preparation method thereof | 宁波长阳科技股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118712660-B | High-porosity dry-method diaphragm for lithium ion battery and preparation method thereof | 宁波长阳科技股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4471145-A1 | SMALL RNA AND USE THEREOF IN TREATMENT OF HYPERLIPIDEMIA | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CN) | 2024-12-04 | — | — | EP | disclosed |
| CN-118712660-A | High-porosity dry-method diaphragm for lithium ion battery and preparation method thereof | 宁波长阳科技股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118712660-A | High-porosity dry-method diaphragm for lithium ion battery and preparation method thereof | 宁波长阳科技股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | ANHUI UNIVERSITY (CN) | 2024-08-13 | — | — | US | disclosed |
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | ANHUI UNIVERSITY (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
| EP-0897903-A2 | Ketone-derivatives of indene, dihydronaphthalene or naphthalene compounds for the treatment of hyperlipidemia | ELI LILLY AND COMPANY (US) | 1999-02-24 | — | — | EP | disclosed |
| WO-1999007360-A1 | COMPOUNDS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
| EP-0352578-A2 | Method of making thin anisotropic films on carriers with structured surfaces | Röhm GmbH (DE) | 1990-01-31 | — | — | EP | disclosed |
| EP-0057503-B1 | PRODUCTION OF HYDROXY ARYLOPHENONES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-20 | — | — | EP | disclosed |
| US-4453010-A | Production of hydroxy arylophenones | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-06-05 | — | — | US | disclosed |
| EP-0057503-A1 | Production of hydroxy arylophenones | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-08-11 | — | — | EP | disclosed |
| US-4339560-A | Process for polymerizing olefins | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1982-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | TLR7, PON1, MYD88 | SMN1; SMN2 412/4885AKR1C3 3143/4885AKR1C2 3079/4885 |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | TLR7, PON1, MYD88 | SMN1; SMN2 395/4885AKR1C3 3550/4885AKR1C2 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.